YH01 / Beijing Yinmei Future Biomedical - LARVOL DELTA

A multicenter Phase I trial of YH01 injection for bladder infusion in patients with moderate to high-risk non-muscular invasive bladder cancer (NMIBC) who have failed to respond to BCG infusion therapy (ChiCTR) - P2 | N=9 | Not yet recruiting | Sponsor: The First Medical Center of the Chinese People's Liberation Army General Hospital; Beijing Yinmei Future Biomedical Technology Co., Ltd.

New P2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor